Thanks for posting this NEJM article Bear. IMO it sets us up for a very big win if we can match or exceed (hopefully), the results of the REDUCE-IT trial with no boogie men in the closet in the form of potential placebo issues. There are other potential issues ahead for Amarin as well. The really big one in our favor would be barriers to entry into the market place. Refining fish oil doesn't seem to be a big problem and many copy cats could be lurking in the wings. Another challenge that could rear its head is the supply of fish to provide this oil while keeping the supply of fish available to keep the species of whales that feed on them sustained. It doesn't look like we would have either of those issues as RVX claims to have a 6 to 10 years lead on the competition and there are no supply chain management issues that would negatively affect another species that we are aware of.
Go RVX go
All IMO, dyoddÂ
tada
